Heart failure management in dialysis patients: Many treatment options with no clear evidence

Bethany Roehm, Gaurav Gulati, Daniel E Weiner, Bethany Roehm, Gaurav Gulati, Daniel E Weiner

Abstract

Heart failure with reduced ejection fraction (HFrEF) impacts approximately 20% of dialysis patients and is associated with high mortality rates. Key issues discussed in this review of HFrEF management in dialysis include dialysis modality choice, vascular access, dialysate composition, pharmacological therapies, and strategies to reduce sudden cardiac death, including the use of cardiac devices. Peritoneal dialysis and more frequent or longer duration of hemodialysis may be better tolerated due to slower ultrafiltration rates, leading to less intradialytic hypotension and better volume control; dialysate cooling and higher dialysate calcium may also have benefits. While high-quality evidence exists for many drug classes in the non-dialysis population, dialysis patients were excluded from major trials, and only limited data exist for many medications in kidney failure patients. Despite limited evidence, beta blocker and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is common in dialysis. Similarly, devices such as implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy that have proven benefits in non-dialysis HFrEF patients have not consistently been beneficial in the limited dialysis studies. The use of leadless pacemakers and subcutaneous ICDs can mitigate future hemodialysis access limitations. Additional research is critical to address knowledge gaps in treating maintenance dialysis patients with HFrEF.

© 2020 Wiley Periodicals LLC.

References

    1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018;137(12):e67–e492. doi:10.1161/CIR.0000000000000558
    1. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2019;73(3S1):A7–A8. doi:10.1053/j.ajkd.2019.01.001
    1. United States Renal Data Sytem. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.
    1. de Bie MK, Ajmone Marsan N, Gaasbeek A, et al. Left ventricular diastolic dysfunction in dialysis patients assessed by novel speckle tracking strain rate analysis: prevalence and determinants. Int J Nephrol. 2012;2012:963504–963504. doi:10.1155/2012/963504
    1. Antlanger M, Aschauer S, Kopecky C, et al. Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis. Kidney Blood Press Res 2017;42(1):165–176. doi:10.1159/000473868
    1. Wang AY-M, Wang M, Lam CW-K, Chan IH-S, Lui S-F, Sanderson JE. Heart failure with preserved or reduced ejection fraction in patients treated with peritoneal dialysis. Am J Kidney Dis. 2013;61(6):975–983. doi:10.1053/j.ajkd.2012.12.030
    1. Sud M, Tangri N, Pintilie M, Levey AS, Naimark DMJ. ESRD and death after heart failure in CKD. J Am Soc Nephrol. 2015;26(3):715–722. doi:10.1681/ASN.2014030253
    1. Charytan DM, Solomon SD, Ivanovich P, et al. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. Am J Kidney Dis. 2017;70(4):522–531. doi:10.1053/j.ajkd.2017.04.018
    1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327. doi:10.1161/CIR.0b013e31829e8776
    1. McIntyre CW, Salerno FR. Diagnosis and Treatment of Intradialytic Hypotension in Maintenance Hemodialysis Patients. Clin J Am Soc Nephrol. 2018;13(3):486–489. doi:10.2215/CJN.11131017
    1. Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int. 2006;69(7):1222–1228. doi:10.1038/sj.ki.5000186
    1. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol. 2009;4(12):1925–1931. doi:10.2215/CJN.04470709
    1. Zoccali C, Moissl U, Chazot C, et al. Chronic Fluid Overload and Mortality in ESRD. J Am Soc Nephrol. 2017;28(8):2491–2497. doi:10.1681/ASN.2016121341
    1. Selby NM, Burton JO, Chesterton LJ, McIntyre CW. Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clin J Am Soc Nephrol. 2006;1(6):1216–1225. doi:10.2215/CJN.02010606
    1. McIntyre CW, Burton JO, Selby NM, et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol. 2008;3(1):19–26. doi:10.2215/CJN.03170707
    1. Chan CT, Greene T, Chertow GM, et al. Effects of frequent hemodialysis on ventricular volumes and left ventricular remodeling. Clin J Am Soc Nephrol. 2013;8(12):2106–2116. doi:10.2215/CJN.03280313
    1. Koch M, Haastert B, Kohnle M, et al. Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail. 2012;14(5):530–539. doi:10.1093/eurjhf/hfs035
    1. Grossekettler L, Schmack B, Meyer K, et al. Peritoneal dialysis as therapeutic option in heart failure patients. ESC Heart Fail. 2019;6(2):271–279. doi:10.1002/ehf2.12411
    1. Pavo N, Yarragudi R, Puttinger H, et al. Parameters associated with therapeutic response using peritoneal dialysis for therapy refractory heart failure and congestive right ventricular dysfunction. PLoS One. 2018;13(11):e0206830. doi:10.1371/journal.pone.0206830
    1. Sun C-Y, Sung J-M, Wang J-D, et al. A comparison of the risk of congestive heart failure-related hospitalizations in patients receiving hemodialysis and peritoneal dialysis - A retrospective propensity score-matched study. PLoS One. 2019;14(10):e0223336. doi:10.1371/journal.pone.0223336
    1. Lu R, Muciño-Bermejo M-J, Ribeiro LC, et al. Peritoneal dialysis in patients with refractory congestive heart failure: a systematic review. Cardiorenal Med. 2015;5(2):145–156. doi:10.1159/000380915
    1. Kazory A, Koratala A, Ronco C. Customization of Peritoneal Dialysis in Cardiorenal Syndrome by Optimization of Sodium Extraction. Cardiorenal Med 2019;9(2):117–124. doi:10.1159/000495703
    1. Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol. 2011;6(6):1326–1332. doi:10.2215/CJN.05200610
    1. Tsujimoto Y, Tsujimoto H, Nakata Y, et al. Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis. Cochrane Database Syst Rev 2019;7:CD012598. doi:10.1002/14651858.CD012598.pub2
    1. Odudu A, Eldehni MT, McCann GP, McIntyre CW. Randomized Controlled Trial of Individualized Dialysate Cooling for Cardiac Protection in Hemodialysis Patients. Clin J Am Soc Nephrol. 2015;10(8):1408–1417. doi:10.2215/CJN.00200115
    1. Brunelli SM, Sibbel S, Do TP, Cooper K, Bradbury BD. Facility Dialysate Calcium Practices and Clinical Outcomes Among Patients Receiving Hemodialysis: A Retrospective Observational Study. Am J Kidney Dis. 2015;66(4):655–665. doi:10.1053/j.ajkd.2015.03.038
    1. Dhamija RK, Tan H, Philbin E, et al. Subcutaneous implantable cardioverter defibrillator for dialysis patients: a strategy to reduce central vein stenoses and infections. Am J Kidney Dis. 2015;66(1):154–158. doi:10.1053/j.ajkd.2015.01.028
    1. El-Chami MF, Clementy N, Garweg C, et al. Leadless Pacemaker Implantation in Hemodialysis Patients: Experience With the Micra Transcatheter Pacemaker. JACC Clin Electrophysiol 2019;5(2):162–170. doi:10.1016/j.jacep.2018.12.008
    1. McGill RL, Ruthazer R, Meyer KB, Miskulin DC, Weiner DE. Peripherally Inserted Central Catheters and Hemodialysis Outcomes. Clin J Am Soc Nephrol. 2016;11(8):1434–1440. doi:10.2215/CJN.01980216
    1. MacRae JM, Pandeya S, Humen DP, Krivitski N, Lindsay RM. Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. Am J Kidney Dis. 2004;43(5):e17–22. doi:10.1053/j.ajkd.2004.01.016
    1. Babadjanov J, Miler R, Niebauer K, Kirksey L. Arteriovenous Fistula Creation for End-Stage Renal Disease May Worsen Pulmonary Hypertension. Ann Vasc Surg. 2016;36:293.e1–293.e3. doi:10.1016/j.avsg.2016.03.020
    1. Ragupathi L, Johnson D, Marhefka GD. Right Ventricular Enlargement within Months of Arteriovenous Fistula Creation in 2 Hemodialysis Patients. Tex Heart Inst J. 2016;43(4):350–353. doi:10.14503/THIJ-15-5353
    1. Reddy YNV, Obokata M, Dean PG, Melenovsky V, Nath KA, Borlaug BA. Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease. Eur Heart J. 2017;38(24):1913–1923. doi:10.1093/eurheartj/ehx045
    1. Hussein WF, Schiller B. Dialysate sodium and intradialytic hypotension. Semin Dial. 2017;30(6):492–500. doi:10.1111/sdi.12634
    1. Paterna S, Gaspare P, Fasullo S, Sarullo FM, Di Pasquale P. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin Sci (Lond) 2008;114(3):221–230. doi:10.1042/CS20070193
    1. Paterna S, Parrinello G, Cannizzaro S, et al. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure. Am J Cardiol. 2009;103(1):93–102. doi:10.1016/j.amjcard.2008.08.043
    1. Zakir RM, Folefack A, Saric M, Berkowitz RL. The use of midodrine in patients with advanced heart failure. Congest Heart Fail. 2009;15(3):108–111. doi:10.1111/j.1751-7133.2008.00042.x
    1. Bergman SM. Hemodialysis in hypotensive heart failure using midodrine. Am J Med Sci. 2009;338(6):470–473. doi:10.1097/MAJ.0b013e3181b7efa7
    1. Cruz DN, Mahnensmith RL, Brickel HM, Perazella MA. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Clin Nephrol 1998;50(2):101–107.
    1. Brunelli SM, Cohen DE, Marlowe G, Van Wyck D. The Impact of Midodrine on Outcomes in Patients with Intradialytic Hypotension. Am J Nephrol 2018;48(5):381–388. doi:10.1159/000494806
    1. Heyse A, Manhaeghe L, Mahieu E, Vanfraechem C, Van Durme F. Sacubitril/valsartan in heart failure and end-stage renal insufficiency. ESC Heart Fail. 2019;6(6):1331–1333. doi:10.1002/ehf2.12544
    1. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. September 2019. doi:10.1056/NEJMoa1911303
    1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720
    1. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi:10.1056/NEJMoa1409077
    1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349–1355. doi:10.1056/NEJM199605233342101
    1. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007.
    1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.
    1. Tieu A, Velenosi TJ, Kucey AS, Weir MA, Urquhart BL. beta-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. Clin J Am Soc Nephrol. 2018;13(4):604–611. doi:10.2215/CJN.07470717
    1. Assimon MM, Brookhart MA, Fine JP, Heiss G, Layton JB, Flythe JE. A Comparative Study of Carvedilol Versus Metoprolol Initiation and 1-Year Mortality Among Individuals Receiving Maintenance Hemodialysis. Am J Kidney Dis. 2018;72(3):337–348. doi:10.1053/j.ajkd.2018.02.350
    1. Tang C-H, Wang C-C, Chen T-H, Hong C-Y, Sue Y-M. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. J Am Heart Assoc 2016;5(1). doi:10.1161/JAHA.115.002584
    1. Cice G, Ferrara L, Di Benedetto A, et al. Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2001;37(2):407–411. doi:10.1016/s0735-1097(00)01158-x
    1. Roy-Chaudhury P, Tumlin JA, Koplan BA, et al. Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. Kidney Int. 2018;93(4):941–951. doi:10.1016/j.kint.2017.11.019
    1. Matsue Y, Suzuki M, Nagahori W, Ohno M, Matsumura A, Hashimoto Y. beta-blocker prevents sudden cardiac death in patients with hemodialysis. Int J Cardiol. 2013;165(3):519–522. doi:10.1016/j.ijcard.2011.09.037
    1. Tangri N, Shastri S, Tighiouart H, et al. beta-Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study. Am J Kidney Dis. 2011;58(6):939–945. doi:10.1053/j.ajkd.2011.06.024
    1. Omae K, Ogawa T, Yoshikawa M, Sakura H, Nitta K. Use of Beta-Blockers on Maintenance Dialysis Patients and Ischemic Cerebral and Cardiovascular Deaths: An Examination Using Propensity Score. Contrib Nephrol 2018;195:120–130. doi:10.1159/000486942
    1. Aoun M, Tabbah R. Beta-blockers use from the general to the hemodialysis population. Nephrol Ther 2019;15(2):71–76. doi:10.1016/j.nephro.2018.10.003
    1. Roberts MA, Pilmore HL, Ierino FL, et al. The beta-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. Am J Kidney Dis. 2016;67(6):902–911. doi:10.1053/j.ajkd.2015.10.029
    1. Arora N, Katz R, Bansal N. Patterns of Angiotensin Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker use with Advanced CKD and risk of ESRD and Death. Kidney Medicine. In press 2020.
    1. Pfeffer JM, Pfeffer MA. Angiotensin converting enzyme inhibition and ventricular remodeling in heart failure. Am J Med. 1988;84(3A):37–44. doi:10.1016/0002-9343(88)90203-3
    1. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005;67(3):799–812. doi:10.1111/j.1523-1755.2005.00145.x
    1. Liu Y, Ma X, Zheng J, Jia J, Yan T. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials. BMC Nephrol. 2017;18(1):206. doi:10.1186/s12882-017-0605-7
    1. Karaboyas A, Xu H, Morgenstern H, et al. DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients. Kidney Int. 2018;94(3):589–598. doi:10.1016/j.kint.2018.03.013
    1. Chang TI, Shilane D, Brunelli SM, Cheung AK, Chertow GM, Winkelmayer WC. Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Am Heart J. 2011;162(2):324–330. doi:10.1016/j.ahj.2011.05.004
    1. Tang C-H, Chen T-H, Wang C-C, Hong C-Y, Huang K-C, Sue Y-M. Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan. Eur J Heart Fail. 2013;15(10):1194–1202. doi:10.1093/eurjhf/hft082
    1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717. doi:10.1056/NEJM199909023411001
    1. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–1321. doi:10.1056/NEJMoa030207
    1. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. doi:10.1056/NEJMoa1009492
    1. Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63(6):528–536. doi:10.1016/j.jacc.2013.09.056
    1. Lin C, Zhang Q, Zhang H, Lin A. Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study. J Clin Hypertens (Greenwich) 2016;18(2):121–128. doi:10.1111/jch.12628
    1. Quach K, Lvtvyn L, Baigent C, et al. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2016;68(4):591–598. doi:10.1053/j.ajkd.2016.04.011
    1. Charytan DM, Himmelfarb J, Ikizler TA, et al. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int. 2019;95(4):973–982. doi:10.1016/j.kint.2018.08.034
    1. Hammer F, Malzahn U, Donhauser J, et al. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int. 2019;95(4):983–991. doi:10.1016/j.kint.2018.11.025
    1. Langote A, Hiremath S, Ruzicka M, McCormick BB. Spironolactone is effective in treating hypokalemia among peritoneal dialysis patients. PLoS One 2017;12(11):e0187269. doi:10.1371/journal.pone.0187269
    1. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–1392. doi:10.1056/NEJMoa1313731
    1. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34–42. doi:10.1161/CIRCULATIONAHA.114.013255
    1. Sibbel S, Walker AG, Colson C, Tentori F, Brunelli SM, Flythe J. Association of Continuation of Loop Diuretics at Hemodialysis Initiation with Clinical Outcomes. Clin J Am Soc Nephrol. 2019;14(1):95–102. doi:10.2215/CJN.05080418
    1. Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001;59(3):1128–1133. doi:10.1046/j.1523-1755.2001.0590031128.x
    1. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–533. doi:10.1056/NEJM199702203360801
    1. Mowry JB, Burdmann EA, Anseeuw K, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila) 2016;54(2):103–114. doi:10.3109/15563650.2015.1118488
    1. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol. 2004;15(8):2195–2203. doi:10.1097/01.ASN.0000135121.81744.75
    1. Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010;21(9):1550–1559. doi:10.1681/ASN.2009101047
    1. Kannel WB, Cupples LA, D’Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. Am Heart J. 1987;113(3):799–804. doi:10.1016/0002-8703(87)90722-8
    1. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006;48(5):e247–346. doi:10.1016/j.jacc.2006.07.010
    1. Normand C, Linde C, Singh J, Dickstein K. Indications for Cardiac Resynchronization Therapy: A Comparison of the Major International Guidelines. JACC Heart Fail. 2018;6(4):308–316. doi:10.1016/j.jchf.2018.01.022
    1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–237. doi:10.1056/NEJMoa043399
    1. Cleland JGF, Daubert J-C, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–1549. doi:10.1056/NEJMoa050496
    1. Makar MS, Pun PH. Sudden Cardiac Death Among Hemodialysis Patients. Am J Kidney Dis. 2017;69(5):684–695. doi:10.1053/j.ajkd.2016.12.006
    1. Pun PH, Al-Khatib SM, Han JY, et al. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis. 2014;64(1):32–39. doi:10.1053/j.ajkd.2013.12.009
    1. Pun PH, Hellkamp AS, Sanders GD, et al. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. Nephrol Dial Transplant. 2015;30(5):829–835. doi:10.1093/ndt/gfu274
    1. Jukema JW, Timal RJ, Rotmans JI, et al. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients. Circulation. 2019;139(23):2628–2638. doi:10.1161/CIRCULATIONAHA.119.039818
    1. Teruya TH, Abou-Zamzam AMJ, Limm W, Wong L, Wong L. Symptomatic subclavian vein stenosis and occlusion in hemodialysis patients with transvenous pacemakers. Ann Vasc Surg. 2003;17(5):526–529. doi:10.1007/s10016-003-0048-4
    1. Baalman SWE, Quast ABE, Brouwer TF, Knops RE. An Overview of Clinical Outcomes in Transvenous and Subcutaneous ICD Patients. Curr Cardiol Rep 2018;20(9):72. doi:10.1007/s11886-018-1021-8
    1. Goldenberg I, Huang DT, Nielsen JC. The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome. Eur Heart J. November 2019. doi:10.1093/eurheartj/ehz788
    1. Friedman DJ, Singh JP, Curtis JP, et al. Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. J Am Coll Cardiol. 2015;66(23):2618–2629. doi:10.1016/j.jacc.2015.09.097
    1. Quader MA, Kumar D, Shah KB, Fatani YI, Katlaps G, Kasirajan V. Safety analysis of intermittent hemodialysis in patients with continuous flow left ventricular assist devices. Hemodial Int. 2014;18(1):205–209. doi:10.1111/hdi.12073
    1. Topkara VK, Coromilas EJ, Garan AR, et al. Preoperative Proteinuria and Reduced Glomerular Filtration Rate Predicts Renal Replacement Therapy in Patients Supported With Continuous-Flow Left Ventricular Assist Devices. Circ Heart Fail. 2016;9(12). doi:10.1161/CIRCHEARTFAILURE.115.002897
    1. Guglielmi AA, Guglielmi KE, Bhat G, Siemeck R, Tatooles AJ. Peritoneal dialysis after left ventricular assist device placement. ASAIO J. 2014;60(1):127–128. doi:10.1097/MAT.0000000000000020
    1. Walther CP, Niu J, Winkelmayer WC, et al. Implantable Ventricular Assist Device Use and Outcomes in People With End-Stage Renal Disease. J Am Heart Assoc. 2018;7(14). doi:10.1161/JAHA.118.008664
    1. Schaefers JF, Ertmer C. Native arteriovenous fistula placement in three patients after implantation of a left ventricular assist device with non-pulsatile blood flow. Hemodial Int. 2017;21(3):E54–E57. doi:10.1111/hdi.12533
    1. Roehm B, Vest AR, Weiner DE. Left Ventricular Assist Devices, Kidney Disease, and Dialysis. Am J Kidney Dis. 2018;71(2):257–266. doi:10.1053/j.ajkd.2017.09.019

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera